Literature DB >> 25444798

Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.

A M Ropero-Álvarez1, A Whittembury2, P Bravo-Alcántara2, H J Kurtis2, M C Danovaro-Holliday2, M Velandia-González2.   

Abstract

As part of the vaccination activities against influenza A[H1N1]pdm vaccine in 2009-2010, countries in Latin American and the Caribbean (LAC) implemented surveillance of events supposedly attributable to vaccines and immunization (ESAVI). We describe the serious ESAVI reported in LAC in order to further document the safety profile of this vaccine and highlight lessons learned. We reviewed data from serious H1N1 ESAVI cases from LAC countries reported to the Pan American Health Organization/World Health Organization. We estimated serious ESAVI rates by age and target group, as well as by clinical diagnosis, and completed descriptive analyses of final outcomes and classifications given in country. A total of 1000 serious ESAVI were reported by 18 of the 29 LAC countries that vaccinated against A[H1N1]pdm. The overall reporting rate in LAC was 6.91 serious ESAVI per million doses, with country reporting rates ranging from 0.77 to 64.68 per million doses. Rates were higher among pregnant women (16.25 per million doses) when compared to health care workers (13.54 per million doses) and individuals with chronic disease (4.03 per million doses). The top three most frequent diagnoses were febrile seizures (12.0%), Guillain-Barré Syndrome (10.5%) and acute pneumonia (8.0%). Almost half (49.1%) of the serious ESAVI were reported among children aged <18 years of age; within this group, the highest proportion of cases was reported among those aged <2 years (53.1%). Of all serious ESAVI reported, 37.8% were classified as coincidental, 35.3% as related to vaccine components, 26.4% as non-conclusive and 0.5% as a programmatic error. This regional overview of A[H1N1]pdm vaccine safety data in LAC estimated the rate of serious ESAVI at lower levels than other studies. However, the ESAVI diagnosis distribution is comparable to the published literature. Lessons learned can be applied in the response to future pandemics.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Events supposedly attributable to vaccines and immunization; Febrile seizures; Guillain-Barré; H1N1; Pandemic influenza; Vaccine safety

Mesh:

Substances:

Year:  2014        PMID: 25444798     DOI: 10.1016/j.vaccine.2014.10.070

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Zika virus infection and pregnancy: Issue for further concern.

Authors:  Viroj Wiwanitkit
Journal:  Obstet Med       Date:  2017-06-19

Review 2.  Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.

Authors:  Edwin J Asturias; Melinda Wharton; Robert Pless; Noni E MacDonald; Robert T Chen; Nicholas Andrews; David Salisbury; Alexander N Dodoo; Kenneth Hartigan-Go; Patrick L F Zuber
Journal:  Vaccine       Date:  2016-05-16       Impact factor: 3.641

3.  International Consensus (ICON): allergic reactions to vaccines.

Authors:  Stephen C Dreskin; Neal A Halsey; John M Kelso; Robert A Wood; Donna S Hummell; Kathryn M Edwards; Jean-Christoph Caubet; Renata J M Engler; Michael S Gold; Claude Ponvert; Pascal Demoly; Mario Sanchez-Borges; Antonella Muraro; James T Li; Menachem Rottem; Lanny J Rosenwasser
Journal:  World Allergy Organ J       Date:  2016-09-16       Impact factor: 4.084

4.  Relief After COVID-19 Vaccination: A Doubtful or Evident Outcome?

Authors:  Mohammed Khaled Al-Hanawi; Noor Alshareef; Rehab H El-Sokkary
Journal:  Front Med (Lausanne)       Date:  2022-01-10

5.  Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.

Authors:  Fengge Wang; Donglan Wang; Yingjie Wang; Cancan Li; Yulu Zheng; Zheng Guo; Pengcheng Liu; Yichun Zhang; Wei Wang; Youxin Wang; Haifeng Hou
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

Review 6.  A review of vaccine effects on women in light of the COVID-19 pandemic.

Authors:  Wen-Han Chang
Journal:  Taiwan J Obstet Gynecol       Date:  2020-09-11       Impact factor: 1.705

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.